Study to find incidence of residual neuromuscular paralysis by using neuromuscular monitor after various doses of neostigmine reversal agent
Phase 4
- Conditions
- Health Condition 1: M00-M99- Diseases of the musculoskeletal system and connective tissue
- Registration Number
- CTRI/2020/08/027270
- Lead Sponsor
- SMS Medical College
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Patients willing to participate in the study.
2.Age group between 20 - 40 years.
3.Weight of the patient between 40-70Kgs.
4.Patients belonging to ASA class-I and II
Exclusion Criteria
1.Obesity (BMI >= 35).
2.Patients with abnormal airway (Mallampati score 3 or more).
3.History of any known neuromuscular disease.
4.Patients with any known cardiac/ respiratory / hepatic or renal disease
5.Patients with known allergy to any drug used in study.
6.Patients taking medication that influences neuromuscular blockade
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To find out the optimum dose of neostigmine for reversal of cisatracurium induced neuromuscular block of different intensity by using neuromuscular monitor (TOF).Timepoint: At baseline when patient is recovering from anesthesia after completion of surgery
- Secondary Outcome Measures
Name Time Method